TP53功能获得型与非功能获得型突变与转移性结直肠癌侧别依赖性预后的差异关联
这项队列研究纳入2017年11月至2021年1月接受下一代测序的1,043例转移性结直肠癌患者,定义R175H、R248W、R248Q、R249S、R273H、R273L和R282W为功能获得型(GOF),其余突变p53为非GOF。结果显示GOF较非GOF mutp53仅在左侧结直肠癌(LCC)中与更差总生存相关(HR=1.66,95%CI 1.20-2.29),在右侧(RCC)中无此关联(HR=0.79,95%CI 0.49-1.26)。RCC较LCC总生存更差仅见于非GOF mutp53亚组(HR=1.76,95%CI 1.30-2.39)。
要点
- 在LCC中,GOF mutp53较非GOF mutp53与更差OS相关(HR=1.66,95%CI 1.20-2.29)。
- 在RCC中,GOF与非GOF mutp53的OS无显著差异(HR=0.79,95%CI 0.49-1.26)。
- RCC较LCC OS更差仅见于非GOF mutp53亚组(HR=1.76,95%CI 1.30-2.39)。
核心结论
- 转移性RCC较LCC生存更差似乎仅限于非GOF mutp53亚组,而GOF较非GOF mutp53与更差生存的关联仅见于LCC患者。
- 将mutp53统一分类为GOF和非GOF为预后分层和理解侧别依赖性预后机制提供了新见解。
- 若得到确认,未来结直肠癌临床试验可能受益于纳入此分类方法。
研究设计与样本
- 这项队列研究纳入2017年11月至2021年1月接受下一代测序的转移性结直肠癌患者,共1,043例。
- 定义R175H、R248W、R248Q、R249S、R273H、R273L和R282W为GOF,其余mutp53为非GOF。
- 采用Cox回归模型分析GOF与非GOF mutp53与总生存的关联,调整年龄、性别、种族、体能状态、Charlson合并症指数和化疗接受情况。
主要发现
- 1,043例患者中,735例肿瘤携带mutp53,308例为野生型p53(wtp53)。
- GOF较非GOF mutp53与更差OS的关联仅见于LCC(HR=1.66,95%CI 1.20-2.29),在RCC中无此关联(HR=0.79,95%CI 0.49-1.26)。
- RCC较LCC与更差OS的关联仅见于非GOF mutp53亚组(HR=1.76,95%CI 1.30-2.39),在GOF mutp53亚组(HR=0.92,95%CI 0.55-1.53)和wtp53亚组(HR=0.88,95%CI 0.60-1.28)中未见。
- 进一步调整RAS、BRAF、PIK3CA突变和微卫星高度不稳定后,这些关联基本不变。
关键数值与推荐
- GOF突变定义为R175H、R248W、R248Q、R249S、R273H、R273L和R282W,其余mutp53为非GOF。
- LCC中GOF vs 非GOF mutp53的OS:HR=1.66(95%CI 1.20-2.29)。
- RCC中GOF vs 非GOF mutp53的OS:HR=0.79(95%CI 0.49-1.26)。
- 非GOF mutp53亚组中RCC vs LCC的OS:HR=1.76(95%CI 1.30-2.39)。
- GOF mutp53亚组中RCC vs LCC的OS:HR=0.92(95%CI 0.55-1.53);wtp53亚组中RCC vs LCC的OS:HR=0.88(95%CI 0.60-1.28)。
临床怎么用
- 原文结论指出,若得到确认,未来结直肠癌临床试验可能受益于纳入将mutp53分类为GOF和非GOF的方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine the association of gain-of-function (GOF) and non-gain-of-function (non-GOF) TP53 mutations with prognosis of metastatic right-sided (RCC) versus left-sided colorectal cancer (LCC). METHODS: This cohort study included patients with metastatic colorectal cancer (CRC) who had next-generation sequencing performed from November 2017 to January 2021. We defined R175H, R248W, R248Q, R249S, R273H, R273L, and R282W as GOF and all other mutp53 as non-GOF. We used Cox regression modeling to examine the association between GOF and non-GOF mutp53 and overall survival (OS), adjusting for age, sex, ethnicity, performance status, Charlson comorbidity index and receipt of chemotherapy. RESULTS: Of total 1,043 patients, 735 had tumors with mutp53 and 308 had wild-type p53 (wtp53). GOF was associated with worse OS than non-GOF mutp53 only in LCC (hazard ratio [HR] = 1.66 [95% CI, 1.20 to 2.29]), but not in RCC (HR = 0.79 [95% CI, 0.49 to 1.26]). Importantly, RCC was associated with worse OS than LCC only in the subset of patients whose CRC carried non-GOF (HR = 1.76 [95% CI, 1.30 to 2.39]), but not GOF mutp53 (HR = 0.92 [95% CI, 0.55 to 1.53]) or wtp53 (HR = 0.88 [95% CI, 0.60 to 1.28]). These associations were largely unchanged after also adjusting for RAS, BRAF, and PIK3CA mutations, and microsatellite instability-high. CONCLUSION: Poorer survival of patients with metastatic RCC versus LCC appeared to be restricted to the subset with non-GOF mutp53, whereas GOF versus non-GOF mutp53 was associated with poorer survival only among patients with LCC. This approach of collectively classifying mutp53 into GOF and non-GOF provides new insight for prognostic stratification and for understanding the mechanism of sidedness-dependent prognosis. If confirmed, future CRC clinical trials may benefit from incorporating this approach.
引用
- Pan M, Jiang C, Tse P, et al. TP53 Gain-of-Function and Non-Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer. J Clin Oncol. 2021. PMID: 34843402. doi:10.1200/JCO.21.02014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。